行情

IMGN

IMGN

ImmunoGen
NASDAQ

实时行情|Nasdaq Last Sale

3.370
+0.100
+3.06%
交易中 14:38 11/22 EST
开盘
3.250
昨收
3.270
最高
3.520
最低
3.250
成交量
109.65万
成交额
--
52周最高
6.13
52周最低
1.760
市值
5.04亿
市盈率(TTM)
-3.3059
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IMGN 新闻

  • Roche Gets CHMP Opinion for Breast Cancer & Lymphoma Drugs
  • Zacks.4天前
  • ImmunoGen: Profiting And Turning Around
  • Seeking Alpha - Article.11/11 16:26
  • Edited Transcript of IMGN earnings conference call or presentation 1-Nov-19 12:00pm GMT
  • Thomson Reuters StreetEvents.11/08 21:34
  • Is ImmunoGen, Inc. (IMGN) A Good Stock To Buy?
  • Insider Monkey.11/07 19:51

更多

所属板块

生物技术和医学研究
+1.67%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

IMGN 简况

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
展开

Webull提供ImmunoGen, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。